COVID-19-associated acute disseminated encephalomyelitis (ADEM).
Anti-Inflammatory Agents
/ therapeutic use
Betacoronavirus
COVID-19
Coronavirus Infections
/ complications
Encephalomyelitis, Acute Disseminated
/ drug therapy
Female
Humans
Immunoglobulins, Intravenous
/ therapeutic use
Methylprednisolone
/ therapeutic use
Middle Aged
Pandemics
Pneumonia, Viral
/ complications
SARS-CoV-2
ADEM
COVID-19
Coronavirus
Demyelinating disease
Post-infectious
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
06
05
2020
accepted:
25
05
2020
revised:
21
05
2020
pubmed:
1
6
2020
medline:
26
9
2020
entrez:
1
6
2020
Statut:
ppublish
Résumé
A 51-year-old woman with COVID-19 infection developed coma and an impaired oculocephalic response to one side. MRI of the brain demonstrated acute multifocal demyelinating lesions, and CSF testing did not identify a direct cerebral infection. High-dose steroids followed by a course of IVIG was administered, and the patient regained consciousness over the course of several weeks. As more patients reach the weeks after initial infection with COVID-19, acute disseminated encephalomyelitis should be considered a potentially treatable cause of profound encephalopathy or multifocal neurological deficits.
Identifiants
pubmed: 32474657
doi: 10.1007/s00415-020-09951-9
pii: 10.1007/s00415-020-09951-9
pmc: PMC7260459
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Immunoglobulins, Intravenous
0
Methylprednisolone
X4W7ZR7023
Types de publication
Case Reports
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
2799-2802Références
Neurology. 2002 Oct 22;59(8):1224-31
pubmed: 12391351
Pediatrics. 2004 Jan;113(1 Pt 1):e73-6
pubmed: 14702500
Neuroradiology. 2007 Feb;49(2):177-83
pubmed: 17131116
Neurology. 2003 Feb 25;60(4):721-2
pubmed: 12601124
Neuroimaging Clin N Am. 2013 May;23(2):245-66
pubmed: 23608688